Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Neurontin: Hurdles To TorPharm Approval Expected To Clear In Jan.

Executive Summary

Pfizer's Neurontin (gabapentin) could face generic competition as early as mid-January

You may also be interested in...



Purepac Gabapentin Is “First Generic” After Pfizer Delists Neurontin Patent

Purepac and Ivax will split "first generic" 180-day exclusivity on their versions of Pfizer's antiepileptic Neurontin (gabapentin)

Purepac Gabapentin Is “First Generic” After Pfizer Delists Neurontin Patent

Purepac and Ivax will split "first generic" 180-day exclusivity on their versions of Pfizer's antiepileptic Neurontin (gabapentin)

Neurontin Bulk Supply May Limit Generic Uptake, Pfizer Says

Neurontin generics will have to overcome limitations in the bulk drug supply in addition to Pfizer's patent defenses, Pfizer CEO Henry McKinnell told a Jan. 22 earnings conference call

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel